Full-Time
Systems Analyst/Platform Owner
Global Security Systems
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$84.5k - $162k/yr
Waukegan, IL, USA
Hybrid
Hybrid role requiring 3 days on-site per week.
Bachelor's
 IT & Security (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- Bachelor 0bashes degree in Information systems, Computer Science, Security Management, Emergency Management, Business Administration, or a related field.
- 5+ years of experience administering enterprise security or incident/crisis/case management platforms
- Proven experience owning global platforms in complex, multi-region environments
- Strong configuration and administration skills across workflows, templates, roles/permissions, data models, and dashboards
- Demonstrated vendor management experience, including SLAs, escalations, QBRs, renewals, and SOWs
- Strong knowledge of change management, UAT/testing, and CAB processes
- Working knowledge of privacy, compliance, and audit requirements
- Excellent communication and stakeholder management skills across diverse global partners
- Lead the global operating model, governance, standards, and control framework for Enterprise Security Systems, including risk monitoring, mass alert notification, and case handling
- Define and manage roles, permissions, and least privilege/data-minimization access
- Maintain and communicate the multi-quarter platform roadmap aligned to business priorities and vendor capabilities
- Lead Quarterly Business Reviews, including performance metrics, issue logs, enhancement backlogs, and action plans
- Publish monthly and quarterly dashboards on usage, delivery success, incident metrics, case throughput, audit completion, and SLA performance
- Support readiness testing, live exercises, and post-incident reviews
- Configure audit programs, ensure chain-of-custody integrity, maintain complete audit trails, and enforce confidentiality controls
- Standardize data models and naming conventions, and partner with BTS to integrate platforms with HR systems, access control, and visitor management solutions
- Support identity lifecycle management, data synchronization, high availability, disaster recovery planning, and Priority 3+ escalations with vendors
- Manage change processes, integration, lead UAT/regression testing and production validation, identify and mitigate risks, and develop role-based training and documentation
- None
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- AbbVie raised 2026 sales guidance to $67.6 billion after Q2 revenue reached $16.99 billion.
- RINVOQ and Skyrizi both grew about 24% in Q2 2026, showing durable demand.
- Apogee closes in Q3 2026, adding long-acting immunology assets for the 2030s.
What critics are saying
- Skyrizi now drives about one-third of 2026 revenue, creating brutal concentration risk.
- UCB’s Bimzelx beat Skyrizi in psoriatic arthritis on May 19, 2026.
- HUMIRA fell 36.1% in Q2 2026; another franchise cliff would crush AbbVie’s growth.
What makes AbbVie unique
- AbbVie’s 2026 scale comes from Skyrizi, Rinvoq, and neuroscience, not one asset.
- The company generates massive free cash flow, funding acquisitions like Apogee Therapeutics in June 2026.
- AbbVie pairs patent-protected biologics with aesthetics and diversification across immunology, oncology, and neuroscience.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie's strong operational performance has not translated into stock gains matching its pharmaceutical peers. The drugmaker achieved 10.4% revenue growth and a 34% operating margin over the past year, ranking second among six key competitors. Despite these results, AbbVie's stock returned 30% over twelve months, trailing Merck's 67% and Johnson & Johnson's 54%. The disconnect appears rooted in market concerns about future competition. Analysts questioned management about competitive dynamics for key immunology drugs SKYRIZI and RINVOQ, which each grew sales 24%. The company trades at 70.1 times earnings but lacks the premium stock performance of peers. The market seems to be pricing in risks that AbbVie's high-performing drugs will face tougher competition, potentially eroding current growth rates and margins.
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics in June 2026, aiming to strengthen its drug pipeline. The biopharmaceutical company reported FY 2025 revenue of nearly $61.2 billion, up roughly 8.6% year-on-year. Net income reached close to $4.2 billion, reflecting a net margin of approximately 6.9%, down from 7.6% the previous year. Free cash flow for the period was nearly $17.8 billion. CVS Health reported FY 2025 revenue of approximately $402.1 billion, representing growth of nearly 7.8%. The integrated healthcare provider serves around 37 million medical members and manages 1.9 billion prescriptions annually through its Health Services segment. Net income was close to $1.8 billion, yielding a net margin of roughly 0.4%, down from 1.2% in FY 2024.
AbbVie has announced a $9.5 billion senior notes offering across multiple tranches with maturities ranging from 2028 to 2066. The offering includes both floating and fixed rate notes, with the largest tranche being $1.5 billion in 6.00% senior notes due 2066. Morgan Stanley, BofA Securities, J.P. Morgan Securities, and SG Americas Securities are serving as joint book-running managers for the transaction. The proceeds will be used for refinancing existing debt, funding acquisitions, and general corporate purposes. The transaction is being conducted under an effective shelf registration statement and the notes are expected to be listed on the New York Stock Exchange. AbbVie confirmed there have been no material adverse changes in its financial position since year-end 2025.
AbbVie reported second-quarter revenue of $16.99 billion, up 10.2% year-on-year and exceeding analyst expectations of $16.79 billion. Adjusted earnings per share of $3.65 also beat consensus estimates of $3.61. The pharmaceutical company's growth was driven by its immunology portfolio, particularly SKYRIZI and RINVOQ, and neuroscience products including Vraylar and Vialev. CEO Robert Michael noted each portfolio "delivered growth above 20%". However, AbbVie lowered its full-year adjusted earnings guidance to $13.97 per share at the midpoint, a 1.5% decrease. Management attributed the revision to anticipated dilution from the planned Apogee Therapeutics acquisition and increased research and development spending. The company faces ongoing biosimilar pressure on legacy products whilst pursuing regulatory approvals for new indications and preparing to launch Tevapadon for Parkinson's disease.
CARE Philippines launches B-STRONG program in Rizal, aims to combat rising cases of hypertension and diabetes. Rizal Province, Philippines (August 4, 2026) - CARE Philippines officially launched the B-STRONG program in the Province of Rizal on July 23. B-STRONG is a partnership between CARE and the AbbVie Foundation that trains and equips Barangay Health Workers in Rizal Province to connect communities to critical healthcare services and improve health outcomes, by delivering care through existing government health systems. In strong partnership with the Department of Health - Center for Health Development Region IV-A (DOH-CHD IV-A), PhilHealth NCR/Rizal, the Rizal Provincial Government, and all its 14 local government units, the program equips more than 3,000 Barangay Health Workers to connect at-risk households to PhilPEN screening, PhilHealth-YAKAP enrollment, and continuous care for non-communicable diseases (NCDs). Representatives from CARE Philippines, DOH Center for Health Development CaLaBaRZon, PhilHealth NCR, the Provincial Government of Rizal, and 14 LGUs from the province gather for the launch of the B-STRONG Project. "In Rizal alone, thousands of people are living with high blood pressure and diabetes, and most have never been screened," said Reiza Dejito, CARE Philippines' Country Director. Despite this reality, she expressed optimism: "Here's what's giving me hope - the care already exists. YAKAP already covers the medicines. The health centers in the LGUs already do the screening. The piece that we can strengthen together is the connection between them. And this is the whole point of B-STRONG, the connection, the bridge, so when a Barangay Health Worker finds a family in need, they help connect them to the care that is already there." Photo: DOH Center for Health Development IV-A and CARE Philippines sign a Memorandum of Understanding. Representing the organizations are (L-R): Glenn Bede Benablo, B-STRONG Project Manager; Dr. Marie Beatrix Duzon, NCD Cluster Head, DOH CHD IV-A; Reiza Dejito, CARE Philippines Country Director; and Jerome Lanit, CARE Philippines Development Portfolio Coordinator. CARE Philippines also formalized their partnership with DOH-CHD IV-A, PhilHealth Regional Office NCR, and the Provincial Government of Rizal through a Memorandum of Understanding (MOU) signing. Vice President of PhilHealth NCR, Dr. Bernadette Lico remarked: "Through the B-STRONG program and its synergy with PhilHealth YAKAP, we are strengthening a more coordinated and sustainable approach - one that emphasizes prevention, health promotion and accessible care at the community level." She added, "as we launch this program today, we reaffirm our collective commitment to stronger health systems and more empowered communities, where every Filipino has the opportunity to live a healthier and more productive life." "This is our north star: to reduce premature mortality due to cardiovascular diseases and diabetes mellitus by 20% by 2028. B-STRONG will reach 10,000 high-risk patients - ensuring that NCDs are diagnosed early, referred timely, and controlled effectively," CARE Philippines B-STRONG Project Manager Glenn Bede Benablo emphasized. The event was attended by over 100 health workers, government partners, and development partners at the municipal, provincial, and regional levels. By embedding the model directly into local health infrastructure, B-STRONG helps ensure access to critical services remains sustainable after the program concludes. The program is designed to last beyond the project period and potentially expand to other locations. "The AbbVie Foundation is committed to driving transformative change in communities, and we are proud to partner with CARE to advance this innovative program that is designed to strengthen local health systems and connect people to the care they need," said Keya Milla, President, AbbVie Foundation; Vice President, Corporate Responsibility & Global Philanthropy, AbbVie. "We look forward to seeing B-STRONG's impact on health outcomes in the Philippines | and its potential to serve as a blueprint for communities around the world." About CARE Founded in 1945 with the creation of the CARE Package(R), CARE is a leading humanitarian organization fighting global poverty. CARE places special focus on working alongside women and girls. Equipped with the proper resources, women and girls have the power to lift whole families and entire communities out of poverty. In 2024, CARE worked in 121 countries, reaching 53 million people through 1,450 projects. In the Philippines, CARE has been supporting the most vulnerable communities during times of crisis while also fostering community resilience and development since 1949. To learn more, visit www.care.org and www.care-philippines.org. About the AbbVie Foundation The AbbVie Foundation is a 501(c)(3) nonprofit committed to driving transformative change in communities worldwide and advancing health equity so that every individual can realize their full potential. Media Contacts: Windel Joshua L. Pasion Project Partnerships Officer 0908 318 9560 | [email protected] Mary Therese L. Norbe Communication Specialist, CARE Philippines 0919 911 7534 | [email protected]